This article is more than 5 years old. Information may no longer be current.

VIDEO: Researchers encouraged by number needed to treat with abaloparatide

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ATLANTA — In this video exclusive, E. Michael Lewiecki, MD, FACP, FACE, director of New Mexico Clinical Research and Osteoporosis Center in Albuquerque, discusses the new osteoporosis drug abaloparatide, a synthetic form of human parathyroid hormone-related protein, designed to stimulate bone formation without also stimulating as much bone resorption as other agents.

Lewiecki reports that the number needed to treat to prevent one vertebral fracture with abaloparatide over 18 months is 28, which is a bit lower than the number needed to treat with teriparatide. In a higher-risk population, similar to that in the Fracture Intervention Trial of alendronate, the number needed to treat is 8, according to Lewiecki’s data.

“The results are encouraging, and if abaloparatide is approved by the FDA, it may be a welcome added benefit to our choices for treating patients with osteoporosis,” Lewiecki said.